Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.09

-1.4%

Nov 4 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: dalroi who wrote (1308)	4/25/2002 9:22:39 AM
From: Arthur Radley	Read Replies (1) of 1475

Stefaan, I'm going to repost Soldier's comments from Yahoo. The enormous comment was about the data that they had to submit to the FDA... Overall....I came away feeling much better about the future...only if MEDI would speed up the process. Maybe with the additional investment on their part for the two new indications....they will get on the "stick". "MEDI-507 by: soldier30 04/25/02 08:36 am Msg: 1744 of 1744 On MEDI's conference call this morning, the company continued to speak positively about the drug and it continues to be the first non-marketed drug featured in Jim Young's discussion of pipeline Analysis of the Phase 2 IV study is under way and the analysis of the 2 sub-Q studies will take place later this quarter and in the next quarter--they are pleased that they will have large amounts of data to review with the FDA Phase 2 data will be presented as it becomes available at appropriate medical meetings Two different psoriatic arthritis trials will begin this quarter, one in combination with sulfasalazine and one in combination with methotrexate --plan on expanding 507's use to multiple other indications this year Re-treatment trial for 507 for psoriasis is to begin shortly to explore "long-term impact of 507 on psoriatic disease" I heard no hint, reference or innuendo to any problem whatsoever with 507's development track--Everything seems very much on track and the psoriatic arthritis program is beoader than I previously expected overall, very favorable for 507

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next